Next‑Generation Sequencing Panel for Bethlem Myopathy, Myofibrillar Myopathy, and Ullrich Muscular Dystrophy in UAE | 2600 AED

Executive Summary & Core Metrics

Diagnostic Accuracy: 99.9% analytical sensitivity and specificity via ISO‑accredited next‑generation sequencing.
Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM.
Post‑Test Guidance: Telephonic clinical interpretation provided by a licensed genetic consultant.
Insurance Direct Billing: Verification available via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This comprehensive NGS panel interrogates all coding exons and flanking ±20 bp intronic regions of genes associated with Bethlem myopathy, myofibrillar myopathy, and Ullrich congenital muscular dystrophy. Variants are confirmed by Sanger sequencing to deliver a definitive molecular diagnosis that guides personalized management, family counseling, and targeted therapy decisions.

Sample Requirements & Preparation

Specimen: 10 mL whole blood (minimum 5 mL) collected in two lavender‑top EDTA tubes.
Storage & Transport: Ship refrigerated at 2–8°C. Do not freeze.
Required Documentation: Duly signed Whole Exome Sequencing Consent Form (Form 37) must accompany the sample.
Home Collection: VIP mobile phlebotomy and cold‑chain courier service available daily 8 AM – 11 PM.

Parameter	Our NGS Panel	Traditional Single‑Gene Sequencing
Precision	>99.9% analytical sensitivity and specificity	Lower sensitivity; restricted to one gene
Methodology	Next‑generation sequencing + Sanger confirmation	Sanger sequencing only
Turnaround Time	40 working days (comprehensive report)	8–12 weeks for multiple genes
Coverage	All coding exons ±20 bp, deep intronic regions	Single gene, partial coverage
Cost‑effectiveness	2600 AED – full panel	Higher cumulative cost for multiple genes

Physician Insight & Safety Protocols

“A definitive molecular diagnosis through comprehensive NGS panel testing is the cornerstone of precision medicine for inherited myopathies. It enables tailored surveillance, targeted interventions, and informed family planning. I strongly recommend that all results be correlated with clinical phenotyping, neurological examination, and three‑generation family history before therapeutic decisions are made.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory – Medication Continuation

Do not discontinue, adjust, or initiate any prescribed medication without direct consultation with your treating physician. This NGS panel is a diagnostic tool and does not replace clinical judgment or ongoing therapeutic monitoring.

Exclusion Criteria & Emergency Red Flags

This test is not intended for acute emergency diagnosis or triage.
If you experience sudden respiratory distress, severe muscle weakness impairing swallowing or breathing, or cardiac arrhythmia, seek immediate emergency medical care.
Individuals with known bleeding disorders, severe anemia, or on anticoagulant therapy must consult a clinician before blood collection.

Patient FAQ & Clinical Guidance

1. What is the purpose of this NGS panel?

This panel identifies disease‑causing variants in genes linked to Bethlem myopathy, myofibrillar myopathy, and Ullrich congenital muscular dystrophy. A precise molecular diagnosis enables tailored disease management, accurate prognosis, reproductive counseling, and eligibility for emerging gene‑targeted therapies.

2. When will I receive my results?

Samples accepted by 9 AM are processed immediately. The final comprehensive report is delivered within 40 working days from the date of sample receipt at the laboratory.

3. How is my genetic data protected and can insurance cover the cost?

All genetic and personal data are processed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Direct billing verification with your insurance provider can be initiated via WhatsApp at +971 54 548 8731.

4. Do I need a doctor’s referral to order this test?

Yes, a referral from a neurologist, geneticist, or primary care physician is required. Our consultant geneticist will review the referral and may request additional clinical documentation to ensure test appropriateness.

5. What happens if a variant of uncertain significance is found?

All variants classified as VUS are reviewed by our multidisciplinary team. Additional segregation studies, functional assays, or re‑analysis after 12 months may be recommended. A telephonic consultation with the reporting geneticist is included in the service to explain the finding and next steps.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under DHA Facility License Number 1143 and adheres fully to UAE federal data protection and health information governance frameworks. All patient genetic data are encrypted, access‑controlled, and processed exclusively within UAE jurisdiction in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Clinical & Logistical Metadata

Test Name	Next‑Generation Sequencing Panel for Bethlem Myopathy, Myofibrillar Myopathy, and Ullrich Muscular Dystrophy
Price (AED)	2600
Turnaround Time	40 working days
Sample Type / Matrix	Whole blood (10 mL, EDTA tubes) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection
Methodology Used	Next‑Generation Sequencing (NGS) + Sanger confirmation
ICD-10-CM Code	G71.0
LOINC Code	55233-1
DHA Facility License & Laboratory Address	License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE